Evaluating patient experience and healthcare utilisation in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

被引:0
|
作者
Siu, Adrian [1 ,2 ]
Steffens, Daniel [1 ,2 ]
Ansari, Nabila [1 ,3 ]
Karunaratne, Sascha [1 ,2 ]
Solanki, Henna [1 ]
Ahmadi, Nima [1 ,3 ]
Solomon, Michael [1 ,2 ,3 ]
Koh, Cherry [1 ,2 ,3 ]
机构
[1] CO Royal Prince Alfred Hosp, Surg Outcomes Res Ctr SOuRCe, POB M157,Missenden Rd, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Fac Med & Hlth, Cent Clin Sch, Sydney, NSW, Australia
[3] Royal Prince Alfred Hosp, Dept Colorectal Surg, Sydney, NSW, Australia
关键词
cytoreductive surgery; geographic disparity; healthcare equity; healthcare utilisation; hyperthermic intraperitoneal chemotherapy; patient experience; peritoneal malignancies; surgical oncology; HIPEC;
D O I
10.1071/AH24192
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective. Approximately 30% of Australians reside in rural communities, where accessing healthcare facilities can be challenging due to considerable distance. This can result in disparities in healthcare equity, subsequently increasing risk of adverse health outcomes, delayed diagnosis, and diminished quality of life. These geographical constraints may be exacerbated in advanced cancers for which treatment is available only at selected centres with appropriate expertise. The aim of this study was therefore to explore the impact of patient residence on experience and healthcare utilisation following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Methods. A retrospective study examined consecutive CRS and HIPEC patients at Royal Prince Alfred hospital from 2017 to 2022. Patients were stratified as metropolitan and regional based on their postcode. Demographics, experiential, and healthcare utilisation data were collected at multiple time points. Statistical analysis included chi-squared and T-tests. Results. Of the 317 participants, 228 (72%) were from metropolitan and 89 (28%) from regional areas. Regional patients tended to rate their hospital experience as 'very good' (P = 0.016). Metropolitan patients were more compliant with surgical follow-up (P < 0.001). No other differences were observed in patient characteristics, experience or healthcare utilisation. Conclusions. The geographical location of patients undergoing CRS and HIPEC for peritoneal malignancies at a major tertiary referral centre did not significantly influence their experience or healthcare utilisation outcomes. Future studies should evaluate long-term healthcare service utilisation or the ramifications of reduced follow-up on recurrence and survival, which will contribute to a deeper understanding of resource allocation in metropolitan and regional Australia, and illuminate its impact on clinical outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis
    Nesher, Eviatar
    Greenberg, Ron
    Avital, Shmuel
    Skornick, Yehuda
    Schneebaunn, Schlomo
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2007, 9 (11): : 787 - 790
  • [22] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer
    Ramakrishnan Ayloor Seshadri
    Olivier Glehen
    World Journal of Gastroenterology, 2016, (03) : 1114 - 1130
  • [23] Robotic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is there a benefit?
    Sparkman, Brian K.
    Freudenberger, Devon C.
    Vudatha, Vignesh
    Trevino, Jose G.
    Khader, Adam
    Fernandez, Leopoldo J.
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2025, 39 (01): : 513 - 521
  • [24] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer
    Newman, N. A.
    Votanopoulos, K. I.
    Stewart, J. H.
    Shen, P.
    Levine, E. A.
    MINERVA CHIRURGICA, 2012, 67 (04) : 309 - 318
  • [25] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?
    Koenigsrainer, Ingmar
    Beckert, Stefan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (38) : 5317 - 5320
  • [26] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
    Gamboa, Adriana C.
    Winer, Joshua H.
    CANCERS, 2019, 11 (11)
  • [27] Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis
    Khan, Hadi M.
    Hanif, Hamza
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (02): : 259 - 261
  • [28] Peritoneal sarcomatosis: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Spiliotis, John
    Kopanakis, Nikolaos
    Prodromidou, Anastasia
    Raptis, Apostolos
    Farmakis, Dimitrios
    Efstathiou, Elias
    SURGICAL INNOVATION, 2021, 28 (03) : 394 - 395
  • [29] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer
    Schmalfeldt, Barbara
    CHIRURGIE, 2022, 93 (12): : 1144 - 1151
  • [30] Evaluating geographical disparities on clinical outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Siu, Adrian
    Steffens, Daniel
    Ansari, Nabila
    Karunaratne, Sascha
    Solanki, Henna
    Ahmadi, Nima
    Solomon, Michael
    Moran, Brendan
    Koh, Cherry
    TECHNIQUES IN COLOPROCTOLOGY, 2024, 28 (01)